

BlueShield. GROWTH HORMONE PEDIATRIC Federal Employee Program. PRIOR APPROVAL REQUEST

Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the physician portion and submit this completed form.

Send completed form to: Service Benefit Plan Prior Approval P.O. Box 52080 MC 139 Phoenix, AZ 85072-2080 Attn. Clinical Services Fax: 1-877-378-4727

Patient Information (required)		Provider Information (required)				
Date:			Provider Name:			
Patient Name:		Specialty:		NPI:		
Date of Birth:	Sex: □Male	□Female	Office Phone:		Office Fax:	
Street Address:			Office Street Address:			
City:	State:	Zip:	City:	Sta	ate:	Zip:
Patient ID: R	1 1 1	1 1	Physician Signature:			
	I	PHYSICIAN	COMPLETES			
For Standard Option Standard Option patient						
1 1	-	<u> </u>	none Pediatrio			·
	NOTE: Form m	nust be complet	ed in its entirety for	processing		
Please select medication:						
□Genotropin	□Norditropin		□Saizen	□Zon	nacton (aka. T	Tev-Tropin)
□Humatrope **Check www.fepblue.org/formulary	Omnitrope	cation is nort of th	□Sogroya			
Is this request for brand or generative states and the second sec		eadon is part of the Seneric	e patient's benefit			
 Is this INITIATION of there 			ıswer helow:			
\square NO – this is a PA renewal				questions on P A	AGE 3	
☐ YES – this is INITIATIO		= -	=			
 Non-Preferred Product Rector Norditropin? ☐Yes a. Does the patient have an 	No* (*If NO, please d	inswer the follow	ving questions)	•		d switch the patien
to Norditropin? □Yes	□No*			1		
*If NO, is there a clin *If YES, please		rying Norditrop	oin? □Yes* □No)		
b. Does the patient require	a reduction of treat	ment burden wi	th fewer injections?	□Yes □No)	
3. Does the patient have radiog	raphic evidence with	nin the last 12 n	nonths of open epiph	nyses? 🗆 Yes	□No	
4. Does the patient have eviden	ce of tumor activity	or active neopl	asm? □Yes □No	0		
5. Will this medication be used hormone? □Yes* □No			ropin agent such as	Serostim, Zorb	tive, or any ot	her growth
*If YES, please specify th						
6. Will this medication be used		υ .	,	□No		
 Norditropin Request (Standallow the member access to a Zomacton (formerly Tev-Tro 	their copay benefit:	Genotropin, Hu				
*If YES, select medication	•	Humatrope	=	-		
	□Saizen □Sky		ogroya \Bar Zoma			
Norditropin Request (Basic the member access to their c			on being requested as	s a change from	Skytrofa or S	Sogroya to allow
*If YES, select medication		□Sogroya				

PLEASE PROCEED TO PAGE 2 FOR DIAGNOSES

PAGE 1 of 3



BlueShield. GROWTH HORMONE PEDIATRIC Federal Employee Program. PRIOR APPROVAL REQUEST

Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the physician portion and submit this completed form.

Send completed form to: Service Benefit Plan Prior Approval P.O. Box 52080 MC 139 Phoenix, AZ 85072-2080 Attn. Clinical Services Fax: 1-877-378-4727

PAGE 2 - PHYSICIAN COMPLETES					
Patient Name:	DOB:	Patient ID: R			
9. What is the patient's diagnosis? □Noonan syndrome □Prade □SHOX (short stature homeobox-c	•	irner syndrome			
☐ Child was born small for gestation a. Has the patient failed to mani ☐ Chronic renal insufficiency	•	2 to 4? □Yes □No			
a. Has the patient had a renal (k	• •				
If NO OR Test Has Not E	est level less than 10? \(\sigma\)Yes Been Done , please answer the	S □No □This test has not been done*	;		
b. Is the patient's height below	-		lone		
☐Idiopathic Short Stature (ISS) aka a. Is the patient's height standar	•				
b. Has it been determined that the	ne growth rate will not permi	it attainment of adult height in normal range? \Box	Yes □No		
c. Did the diagnostic evaluation means? □Yes □No	exclude other causes associa	ated with short stature that should be observed or	r treated by other		
☐Other (please specify):					

PAGE 2 of 3



BlueShield. GROWTH HORMONE PEDIATRIC Federal Employee Program. PRIOR APPROVAL REQUEST

Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the physician portion and submit this completed form.

Send completed form to: Service Benefit Plan Prior Approval P.O. Box 52080 MC 139 Phoenix, AZ 85072-2080 Attn. Clinical Services Fax: 1-877-378-4727

Patient Information (required)		Provider Information (required)					
Date:			Provider Name:				
Patient Name:			Specialty:		NPI:		
Date of Birth:	Sex: □Male	□Female	Office Phone:		Office Fax	x:	
Street Address:			Office Street Address:				
City:	State:	Zip:	City:	St	State: Zip:		
	State.	Zip.		54		2.ip.	
Patient ID: R	<u> </u>		Physician Signature:				
	P	'HYSICIAN	COMPLETES				
For Standard Option Standard Option patient			product. Please consident can receive up to 2 f				
CO	ONTINUATI(ON OF TH	HERAPY (PA 1	RENEWA	L)		
	Gro	owth Horr	none Pediatric	•			
	NOTE: Form m	nust be comple	ted in its entirety for	processing			
Please select medication:							
□Genotropin □Humatrope	□Norditropin □Omnitrope		□Saizen □Sogroya	□Zon	nacton (ak	a. Tev-Tropin)	
**Check www.fepblue.org/formulary	-	cation is part of t					
Is this request for brand or gene		leneric	To patient a senere				
1. Is this INITIATION of there			nswer below:				
☐ YES – this is INITIATIO							
□NO – this is a PA renewal		_		uestions below	7:		
2. Non-Preferred Product Reto Norditropin?	quest (Standard Op No* (*If NO, please a			rticipate in thi	s program	and switch the patien	
a. Does the patient have an	· · · · · · · · · · · · · · · · · · ·	=		dequate treatm	ent respon	ise	
to Norditropin? □Yes	□No*						
*If NO, is there a clin			_				
b. Does the patient require		ment burden w	ith fewer injections?	□Yes □No)		
3. What is the patient's diagnos		O 411	1 6"			4.1	
□Noonan syndrome □Prader-Willi syndrome			one deficiency (inadequate secretion of endogenous growth hormone)				
□ Prader-Willi syndrome □ Idiopathic Short Stature (ISS) aka non-growth hormone-deficient short stature □ Turner syndrome □ SHOX (short stature homeobox-containing gene deficiency)							
□Chronic renal insufficienc		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		mg gene deriese	11037		
a. Has the patient had a	•	olant? □Yes	□No				
□Child was born small for g	gestational age						
a. Has the patient failed	to manifest catch-up	growth by ag	e 2 to 4? □Yes □1	No			
☐Other (please specify):							
4. Does the patient have radiogram	aphic evidence with	in the last 12 r	nonths of open epiphy	yses? □Yes	□No		
5. Does the patient have eviden	ce of tumor activity	or active neop	lasm? □Yes □No				
6. Does the patient have a grow	th velocity of more	than 2cm per y	vear? □Yes □No				
7. Is the patient experiencing ar	ny significant side ef	fects? \(\sigma\)Yes	□No				
8. Has the patient been complia	nt with therapy?	Yes □No					
9. Will this medication be used hormone? □Yes* □No				erostim, Zorb	tive, or any	y other growth	
10. Will this medication being	used in combination	with Voxzogo	(vosoritide)? \(\square\)Yes	□No			